- Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?
-
Jin Q, Yang RX, Fan JG
- KMID: 2531370
- Clin Mol Hepatol.
- 2022 Jul;28(3):473-477.
- doi: 10.3350/cmh.2022.0155
-
- CITED
-
- Close
- SHARE
-
- Close
- Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
-
Ren TY, Li XY, Fan JG
- KMID: 2511453
- Clin Mol Hepatol.
- 2021 Jan;27(1):83-86.
- doi: 10.3350/cmh.2020.0298
-
- CITED
-
- Close
- SHARE
-
- Close
- Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
-
Ren TY, Eslam M, Fan JG
- KMID: 2560122
- Clin Mol Hepatol.
- 2024 Oct;30(4):1039-1041.
- doi: 10.3350/cmh.2024.0801
-
- CITED
-
- Close
- SHARE
-
- Close
- Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”
-
Ren TY, Eslam M, Fan JG
- KMID: 2560061
- Clin Mol Hepatol.
- 2024 Oct;30(4):649-652.
- doi: 10.3350/cmh.2024.0558
-
- CITED
-
- Close
- SHARE
-
- Close
- Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
-
Shi Yw, Fan JG
- KMID: 2539804
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S228-S243.
- doi: 10.3350/cmh.2022.0401
Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD) characterized by steatosis-associated inflammation and liver injury. Without effective treatment or management, NASH can have life-threatening outcomes.... -
- CITED
-
- Close
- SHARE
-
- Close
